Literature DB >> 16210143

High prevalence of pulmonary arterial thrombi in donor lungs rejected for transplantation.

Lorraine B Ware1, Xiaohui Fang, Yibing Wang, Wayne D Babcock, Kirk Jones, Michael A Matthay.   

Abstract

BACKGROUND: Donor hypoxemia is a common reason for the rejection of lungs for transplantation. Organ donors are at high risk for venous thromboembolism. Pulmonary arterial thrombosis could contribute to donor hypoxemia. The primary objective of this study was to prospectively quantify the incidence of pulmonary arterial thrombosis in organ donors whose lungs were rejected for transplantation. The secondary objective was to better define the spectrum of histologic abnormalities in the same group of lungs.
METHODS: A complete gross pathologic and histologic analysis of whole lung specimens was done on lungs from 17 donors whose lungs were rejected for transplantation. Lungs had not been flushed with a pulmonary preservation solution.
RESULTS: Overall, 35% of the donors had gross or microscopic evidence of either pulmonary arterial thrombosis, pulmonary infarction, or both. Clinical characteristics, including oxygenation, were not significantly different between donors who had thrombi or infarction and donors who did not. Other pathologic findings included bronchopneumonia (focal or early in 4/17, moderate or severe in 8/17), respiratory bronchiolitis (7/17) and centriacinar emphysema (7/17).
CONCLUSIONS: Pulmonary arterial thrombosis and/or pulmonary infarction are very common in organ donors whose lungs are rejected for transplantation and might contribute to lung dysfunction both in lung donors and lung recipients. Further studies are needed to define the incidence of pulmonary arterial thrombosis in organ donors whose lungs are used for transplantation and to better assess the adverse clinical consequences of donor pulmonary arterial thrombosis in lung recipients.

Entities:  

Mesh:

Year:  2005        PMID: 16210143     DOI: 10.1016/j.healun.2004.11.011

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

1.  The 4G/4G genotype of the PAI-1 (serpine-1) 4G/5G polymorphism is associated with decreased lung allograft utilization.

Authors:  A Sapru; J G Zaroff; L Pawlikowska; K D Liu; K K Khush; L A Baxter-Lowe; V Hayden; R L Menza; M Convery; V Lo; A Poon; H Kim; W L Young; J Kukreja; M A Matthay
Journal:  Am J Transplant       Date:  2012-03-05       Impact factor: 8.086

2.  Warm retrograde perfusion can remove more fat from lung grafts with fat embolism in a porcine model.

Authors:  Masahiro Irie; Shinji Otani; Takeshi Kurosaki; Shin Tanaka; Takashi Ohki; Kentaroh Miyoshi; Seiichiro Sugimoto; Masaomi Yamane; Takahiro Oto; Shinichi Toyooka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-11-12

3.  Cell replacement in human lung bioengineering.

Authors:  Brandon A Guenthart; John D O'Neill; Jinho Kim; Kenmond Fung; Gordana Vunjak-Novakovic; Matthew Bacchetta
Journal:  J Heart Lung Transplant       Date:  2018-11-22       Impact factor: 10.247

4.  Acute Massive and Submassive Pulmonary Embolism: Historical Considerations/Surgical Techniques of Pulmonary Embolectomy/Novel Applications in Donor Lungs with Pulmonary Emboli.

Authors:  Cody Russell; Suresh Keshavamurthy
Journal:  Int J Angiol       Date:  2022-09-23

5.  Clinical Outcomes of Lung Transplants From Donors With Unexpected Pulmonary Embolism.

Authors:  Yuriko Terada; Jason M Gauthier; Michael K Pasque; Tsuyoshi Takahashi; Jingxia Liu; Ruben G Nava; Ramsey R Hachem; Chad A Witt; Derek E Byers; Rodrigo Vazquez Guillamet; Benjamin D Kozower; Bryan F Meyers; Patrick R Aguilar; Hrishikesh S Kulkarni; G Alexander Patterson; Daniel Kreisel; Varun Puri
Journal:  Ann Thorac Surg       Date:  2020-10-22       Impact factor: 5.102

Review 6.  Donation after circulatory death donors in lung transplantation.

Authors:  Thomas M Egan; Benjamin E Haithcock; Jason Lobo; Gita Mody; Robert B Love; John Jacob Requard; John Espey; Mir Hasnain Ali
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 3.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.